Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry
Technical Report,22 May 2019,21 May 2020
Uniformed Services University Bethesda United States
Pagination or Media Count:
The purpose of this study is to investigate possible pharmacogenomic risk factors for mefloquine neurotoxicity and potentially find markers that may differentiate between mefloquine toxicity and PTSD. This study is a pilot study powered to find large, clinically significant differences in genetic variants along with exploratory objectives aimed at looking for trends in symptom complexes, environmental interactions with various genetic markers and differences between mefloquine toxicity and PTSD. The subject population includes anyone with a mefloquine exposure history or diagnosis of PTSD without mefloquine exposure. The study is a cross-sectional case-control study. The protocol has been approved by the USUHS IRB and the business contract is currently being reviewed.
- Medicine and Medical Research